JP2005537032A - アドザイムおよびその用途 - Google Patents

アドザイムおよびその用途 Download PDF

Info

Publication number
JP2005537032A
JP2005537032A JP2004569756A JP2004569756A JP2005537032A JP 2005537032 A JP2005537032 A JP 2005537032A JP 2004569756 A JP2004569756 A JP 2004569756A JP 2004569756 A JP2004569756 A JP 2004569756A JP 2005537032 A JP2005537032 A JP 2005537032A
Authority
JP
Japan
Prior art keywords
adzyme
substrate
catalytic domain
targeting moiety
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004569756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537032A5 (enExample
Inventor
ノウバル ビー． アフェヤン
ブライアン ベインズ
リュチラ ダスグプタ
フランク ディ． リー
ゴードン ジー． ウォン
Original Assignee
コンパウンド セラピューティクス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンパウンド セラピューティクス インコーポレーティッド filed Critical コンパウンド セラピューティクス インコーポレーティッド
Publication of JP2005537032A publication Critical patent/JP2005537032A/ja
Publication of JP2005537032A5 publication Critical patent/JP2005537032A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004569756A 2002-08-27 2003-08-27 アドザイムおよびその用途 Pending JP2005537032A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40651702P 2002-08-27 2002-08-27
US42375402P 2002-11-05 2002-11-05
US43000102P 2002-11-27 2002-11-27
PCT/US2003/026937 WO2004019878A2 (en) 2002-08-27 2003-08-27 Adzymes and uses thereof

Publications (2)

Publication Number Publication Date
JP2005537032A true JP2005537032A (ja) 2005-12-08
JP2005537032A5 JP2005537032A5 (enExample) 2006-10-19

Family

ID=31982336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004569756A Pending JP2005537032A (ja) 2002-08-27 2003-08-27 アドザイムおよびその用途

Country Status (6)

Country Link
US (2) US20040081647A1 (enExample)
EP (1) EP1539941A4 (enExample)
JP (1) JP2005537032A (enExample)
AU (1) AU2003262937B2 (enExample)
CA (1) CA2497047A1 (enExample)
WO (1) WO2004019878A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159441A (ja) * 2007-01-17 2014-09-04 Immunomedics Inc 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
JP2019537432A (ja) * 2016-10-04 2019-12-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 標的化エフェクタータンパク質およびその使用
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU2001277867B2 (en) 2000-07-11 2006-12-07 Research Corporation Technologies, Inc. Artificial antibody polypeptides
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
EP2444810A3 (en) * 2002-10-02 2013-01-02 Catalyst Biosciences, Inc. Proteases mutants with altered specificity and uses thereof
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US7790762B2 (en) 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
AU2005244271B2 (en) 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
JP2009502121A (ja) * 2005-07-01 2009-01-29 アクセルロン ファーマ インコーポレーテッド Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用
WO2007030708A2 (en) * 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
WO2008048685A2 (en) * 2006-10-19 2008-04-24 Duke University Ox40 aptamers
MY157916A (en) 2006-07-21 2016-08-15 Xyleco Inc Conversion system for biomass
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US7680553B2 (en) * 2007-03-08 2010-03-16 Smp Logic Systems Llc Methods of interfacing nanomaterials for the monitoring and execution of pharmaceutical manufacturing processes
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
SG172985A1 (en) * 2009-01-15 2011-08-29 Glutagen Pty Ltd Compositions for the treatment of gluten intolerance and uses thereof
WO2011050263A2 (en) * 2009-10-23 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy
ITBG20120050A1 (it) * 2012-10-29 2013-01-28 Michele Mutti Proteina di fusione con attività proteasica e specificità degli anticorpi
EP3445400A1 (en) * 2016-04-22 2019-02-27 Medimmune Limited Conjugated protease targeting moieties
MX2020012252A (es) * 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
WO2025114429A1 (en) * 2023-11-29 2025-06-05 Intract Pharma Ltd Transcytosing composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
EP0355068A3 (en) * 1988-08-19 1991-09-04 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and their use
WO1991012328A1 (en) * 1990-02-15 1991-08-22 Fowlkes Dana M Totally synthetic affinity reagents
US5961973A (en) * 1992-03-06 1999-10-05 Crea; Roberto Pathogen-targeted biocatalysts
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6399355B1 (en) * 1995-06-07 2002-06-04 The Trustees Of Columbia University In The City Of New York Non-naturally occurring targeted lipolytic compounds and related compositions and methods
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
DE19643314A1 (de) * 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US6406846B1 (en) * 1997-10-14 2002-06-18 David Whitcomb Method for determining whether a human patient is susceptible to hereditary pancreatitis, and primers therefore
US6159722A (en) * 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US6627744B2 (en) * 1999-07-02 2003-09-30 Genencor International, Inc. Synthesis of glycodendrimer reagents
EP1364009A2 (en) * 2000-06-15 2003-11-26 Board of Regents, The University of Texas System Regulatable, catalytically active nucleic acids
AU2001290178A1 (en) * 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20030068792A1 (en) * 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
WO2003022858A2 (de) * 2001-09-11 2003-03-20 Nascacell Gmbh Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159441A (ja) * 2007-01-17 2014-09-04 Immunomedics Inc 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
JP2019537432A (ja) * 2016-10-04 2019-12-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 標的化エフェクタータンパク質およびその使用
US11603394B2 (en) 2016-10-04 2023-03-14 University Of Florida Research Foundation, Incorporated Targeted effector proteins and uses thereof
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof

Also Published As

Publication number Publication date
AU2003262937A1 (en) 2004-03-19
EP1539941A4 (en) 2006-11-29
WO2004019878A2 (en) 2004-03-11
US20040081647A1 (en) 2004-04-29
EP1539941A2 (en) 2005-06-15
US20040081648A1 (en) 2004-04-29
CA2497047A1 (en) 2004-03-11
WO2004019878A3 (en) 2004-07-15
AU2003262937B2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
EP1730198B1 (en) Adzymes and uses thereof
JP2005537032A (ja) アドザイムおよびその用途
JP7773579B2 (ja) 改変された膜型セリンプロテアーゼ１（ｍｔｓｐ－１）ポリペプチドおよび使用方法
KR102501921B1 (ko) 유도성 결합 단백질 및 사용 방법
CA2339331C (en) Expression and export of angiogenesis inhibitors as immunofusins
US20040259155A1 (en) Methods of engineering spatially conserved motifs in polypeptides
JP2005537032A5 (enExample)
CN101384621A (zh) 产生受体和配体同种型的方法
US11613744B2 (en) Modified urokinase-type plasminogen activator polypeptides and methods of use
CN109790526A (zh) 优化的二核酸酶融合体和方法
US12331334B2 (en) Modified urokinase-type plasminogen activator polypeptides and methods of use
EP4565256A2 (en) Il-18 fusion proteins and methods of producing il-18
JP2014502965A (ja) ｕＰＡＲアンタゴニストおよびその使用
WO2024229117A2 (en) Methods of using il-18 fusion proteins
WO2007030708A2 (en) Antimicrobial adzymes and uses thereof
JPH1175879A (ja) プロテインジスルフィドイソメラーゼを含有する融合タンパク質をコードするｄｎａ
EA047381B1 (ru) Модифицированные пептиды сериновой протеазы 1 мембранного типа (mtsp-1) и способы применения
HK40032913A (en) Constrained conditionally activated binding proteins
HK1210189A1 (en) Method for the production and selection of molecules comprising at least two different entities and uses thereof
MXPA01001970A (en) Expression and export of angiostatin and endostatin as immunofusis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090603

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100106